Innate Pharma (IPH) — Cash Flow Reinvestment Rate
Latest as of June 2024:
0.09x
Innate Pharma (IPH) has a Cash Flow Reinvestment Rate of 0.09x as of June 2024, reinvesting €283.00K (capex €283.00K ) from operating cash flow of €3.04 Million. Check Innate Pharma cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
0.09x
(Capex + Investments) / Operating CF
Total Reinvested
€283.00K
Capex + Investments
Operating Cash Flow
€3.04 Million
EUR
Capital Expenditures
€283.00K
EUR
Innate Pharma Cash Flow Reinvestment Rate (2006–2019)
Historical reinvestment intensity for Innate Pharma across 4 annual periods. Explore IPH long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Innate Pharma (2006–2019)
Year-by-year capital reinvestment analysis for Innate Pharma. For live market cap and broader valuation context, see Innate Pharma (IPH) market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 3.65x | €127.52 Million | €34.92 Million | €65.40 Million | ▲ +515.9% |
| 2015 | 0.59x | €123.27 Million | €207.91 Million | €7.40 Million | ▲ +2291.1% |
| 2011 | 0.02x | €322.00K | €12.99 Million | €322.00K | ▼ -98.8% |
| 2006 | 2.09x | €752.00K | €360.00K | €752.00K | — |
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow